Orion - Other information disclosed according to the rules of the Exchange

398,245 Orion Corporation A shares converted into B shares

ORION CORPORATION      STOCK EXCHANGE RELEASE 19 APRIL 2017 at 9.00 a.m.
EEST


398,245 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion
Corporation, 398,245 A shares have been converted into 398,245 B shares. The
conversion has been entered into the Trade Register on 19 April 2017.

The total number of shares in Orion Corporation is 141,257,828 which, after the
conversion, consists of 37,702,028 A shares and 103,555,800 B shares. The number
of votes of the company's shares is after the conversion 857,596,360.



Orion Corporation



Olli Huotari               Jari Karlson
SVP, Corporate Functions   CFO




Contact person:
Terhi Ormio, Vice President, Communications, tel. +358 10 426 4646



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish pharmaceutical company - a builder of
well-being. Orion develops, manufactures and markets human and veterinary
pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The
company is continuously developing new drugs and treatment methods. The core
therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS)
disorders, oncology and respiratory for which Orion developes inhaled Easyhaler®
pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the
company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq
Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.



[]